Oorjaa's ‘Songs of Nature' Lights Up Sustainable Design
Known for transforming materials like banana fibre, lantana, cork, and granite dust into sculptural lighting, Oorjaa brings together signature pieces and a new collection inspired by the quiet intelligence of nature. But Songs of Nature is more than a design display—it's a space for dialogue and reflection, bringing together artists, designers, and sustainability thinkers.
Visitors can take part in talks, panels, and hands-on workshops, all centered on exploring the purpose and impact of creative practices. The event seeks to foster a deeper understanding of material intelligence and circular design—questioning how we make, why we make, and how our choices shape the world around us.
Jenny Pinto, Founder and Design Director of Oorjaa, shared, 'Songs of Nature is a chance to pause and listen — not just to ideas and conversations, but to the deep, often invisible systems that shape our material world. We hope it sparks curiosity, care, and a renewed sense of connection to how and why we create.'
Set within Sabha, a restored 160-year-old colonial school, the event combines heritage architecture with contemporary sustainable design. It invites guests to experience lighting not just as decor, but as poetry made tangible—expressing the values of care, craft, and environmental responsibility.
Step into Songs of Nature and discover how conscious creativity and natural materials can illuminate both spaces and minds.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
US stocks tend to gain around Fed's Jackson Hole summer conference, analysis shows
By Lewis Krauskopf NEW YORK (Reuters) -U.S. stocks have tended to fare well around the Federal Reserve's Jackson Hole gathering in August, according to a historical analysis from DataTrek Research, although the market has seen sizable moves in both directions in recent years. The Fed's annual Wyoming research conference is set for Thursday through Saturday, and Chair Jerome Powell's speech on Friday is expected to be the main event for markets. DataTrek looked at the benchmark S&P 500 in the five trading days before and after the Fed chair's speech since 2010. The index gained an average of 0.9% over the period, with the bulk after the speech. "This suggests that markets get incremental clarity from the chair's speech, which in turn boosts equity valuations," Nicholas Colas, DataTrek's co-founder, said in a research note. This year, the S&P 500 has slipped in the lead-up to the speech so far, Colas said in the note published early Tuesday. "This goes against the usual pattern, so we would not be surprised to see the index rally modestly through Thursday," he said. One notable exception to the trend was in 2022, when the index slumped 7.4% in the 10-day period. That year at Jackson Hole, Powell warned of slower growth as the Fed fought high inflation. The S&P 500 fell over 19% for the full year 2022 as the Fed raised interest rates. In 2023, the index gained 3.3% in the studied period. DataTrek noted the S&P 500 fell in 2013 and 2015 when Fed chairs Ben Bernanke and Janet Yellen did not attend the symposium. This year, investors are eager to see if Powell reinforces expectations of a central bank interest rate cut at its September 16-17 meeting. Recent weak labor market data bolstered those expectations. Fed Fund futures on Tuesday were pricing in an 84% chance of such a move, according to LSEG data.
Yahoo
24 minutes ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.
Yahoo
24 minutes ago
- Yahoo
6 Chiefs won't practice on Tuesday; Steve Spagnuolo weighs in
Ahead of their practice at their home facility at the Truman Sports Complex on Tuesday, the Kansas City Chiefs listed six players who would not take the field due to injury or illness: linebacker Jack Cochrane (knee bruise), offensive lineman Ethan Driskell (appendectomy), safety Mike Edwards (hamstring), cornerback Nazeeh Johnson (shoulder), defensive tackle Omarr Norman-Lott (ankle) and wide receiver Jalen Royals (knee). Late Monday afternoon, Kansas City placed defensive end Felix Anudike-Uzomah on the Reserve/Injured list. Even though he is practicing, cornerback Kristian Fulton has yet to play in a preseason game as he recovers from offseason knee surgery. 'Well, the unknown is Kristian right now because we haven't had him out there,' said defensive coordinator Steve Spagnuolo. 'Jaylen [Watson] has missed some time, and now we've got [Johnson], who is a little dinged up. More than any group on the defense, that back end has to have a lot of continuity, and that comes with reps. So with a couple of different moving pieces, there's a little bit of concern there, so hopefully we can start to gel that together.' The Chiefs play their final game of the 2025 preseason against the Chicago Bears at home on Friday at 7:20 p.m. Arrowhead Time. Chiefs head coach Andy Reid has already confirmed that the starters will see playing time.
